<DOC>
	<DOCNO>NCT01086969</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity single dose Menactra® vaccine support registration . Primary Objectives : - To describe antibody titer measure serum bactericidal activity use baby rabbit complement ( SBA-BR ) Menactra® vaccination . - To describe safety profile participant one dose Menactra® .</brief_summary>
	<brief_title>A Study Meningococcal Vaccine , Menactra® Healthy Subjects India</brief_title>
	<detailed_description>Participants enrol three age cohort : Children : 2 - 11 year age ; Adolescents : 12 - 17 year age , Adults : 18 - 55 year age receive single dose Menactra® . They follow duration 30 day vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 11 year Aged 12 17 year Aged 18 55 year age day inclusion For participant age 2 11 year : Provision inform consent form sign parent ( ) legal representative . For participant age 12 17 year : Provision assent form sign participant inform consent form sign parent ( ) legal representative . For participant age 18 55 year : Provision inform consent form sign participant . If participant participant 's parent legally accept representative ( participant age 2 17 year ) illiterate , independent witness require sign consent form . Participant parent/legally acceptable representative ( applicable ) able attend schedule visit comply trial procedure For woman childbearing potential , sexually active , use medically acceptable effective method contraception least 4 week prior vaccination , least 4 week vaccination ( applicable participant age 2 17 year ' female childbearing potential sexually active ) Exclusion Criteria : For woman childbearing potential sexually active , know suspected pregnancy positive serum/urine pregnancy test ( applicable participant age 2 17 year ' female childbearing potential sexually active ) Breastfeeding woman Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness , stage could interfere trial conduct completion , opinion investigator Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt plan receipt vaccine ( influenza vaccine give 2 week vaccination ) 4 week precede follow trial vaccination Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface ( HBs ) antigen , Hepatitis C seropositivity report participant/parent/guardian and/or base medical history History document invasive meningococcal disease Previous vaccination meningococcal disease either trial vaccine another vaccine Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular vaccination Subjects deprive freedom administrative court order , emergency setting , hospitalize without his/her consent Personal family history GuillainBarré Syndrome Temporary contraindication delay vaccination resolve : Febrile illness ( temperature ≥38.0°C ) moderate severe acute illness/infection day vaccination Received oral inject antibiotic therapy within 72 hour prior blood draw</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Meningococcal Infection</keyword>
	<keyword>Meningitis , Bacterial</keyword>
	<keyword>Menactra®</keyword>
</DOC>